Gut Call On Puma Biotechnology, Inc. (PBYI): Now It’s Really Down Too Much

Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the hottest stocks trading today on the U.S. Markets as the company shares are 2.56% or 0.32 points lower from last closing price of $12.49, reaching $12.17 at last check. Any clue why there is so much of action in the PBYI stock? The share price is losing for the fifth day in a row and has dropped in 2 of the last 5 days and is down -7.21% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -2,468,325 shares, and in total 160975 shares valued at $1.959 million were seen changing hands compared with 2.629 million shares valued at $32.84 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the PBYI stock is near its bottom.

Puma Biotechnology, Inc. (PBYI) shares have notched a 3-month decline of about -7.21%, but has still tumbled -38.62% year to date. By comparison, the stock sank -73.59% over the past 12 months, while it jumped 11.92% over the 1 month. The company’s market cap is around $495.35M, with its short interest ratio standing at 6.27%.

In the current trading session for PBYI, the stock witnessed two major price actions, it rose to a high of $12.99 and was down as much as $11.65 at one point. The high recorded is very low when compared to their 52-week high which is $8.45. The 52-week high is now at -75.39 distance from current price. Their recent low of $50.75 represents a 47.81% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for PBYI is $18.63, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Puma Biotechnology, Inc. earned $-2.41 per share in the trailing 12 months and has a P/E ratio of -5.05. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 30.46 and lower compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. PBYI also has P/S multiple of 1.68. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.34x.

The company recorded an interesting insider sale transaction by the CEO on Sep 04, 2019. A Securities and Exchanges Commission filings show that Alan H Auerbach sold a total of 524 PBYI shares that day for a sum of around $5,313. The filings show that the insider now retains 4,188,484 shares, currently worth $50,973,850. Puma Biotechnology, Inc. (PBYI) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 18,222 shares. In total, individual insiders traded 18,222 shares in the business, which makes up 9.163% of 198,863 shares that were traded over a year. In the past 12 months, insiders have purchased 156,130 shares while the seller parted with 42,733 shares.

PBYI‘s last price was down -43.64% as compared to the average trading price of 50 days recorded at $21.59 while enlarging the period to 200 trading days, the average closing price was $10.34. At present, there are 39.66 million in the total number of common shares owned by the public and among those 34.52 million shares have been available to trade. The percentage of shares being held by the company management was 11.2% while institutions stake was 91.5%. The company has generated negative returns on equity over the last 12 months (-254.1%). It managed to keep its gross profit margin at 87.2% over the past 12 months.

When assessing the full upside of the PBYI stock, there is another set of technicals that should be looked into and considered. Its 16.73% gain from moving average of $10.43 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 1.59 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Puma Biotechnology, Inc. — 0 analysts rate the stock as a buy with another 0 rating it strong buy. There are 7 analysts who maintain a hold rating for the stock, with 3 giving it a sell rating. Analysts arrived at a 12-month price target of $19.25 on shares of Puma Biotechnology, Inc. (NASDAQ:PBYI), which corresponds to 60.82% upside potential than its current market price of $12.17 and implies potential despite the recent drop in the price. However, their current target price has fallen from $19.25 a month ago and is down handily from the consensus target of $24.125 a quarter ago.

In the last five years, the EPS of the company has been roughly -9.5%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded an increase of 6.1%, but this figure is rather unattractive.